Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Pulmonary Atelectasis D001261 1 associated lipids
Neurologic Manifestations D009461 1 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Brain Hemorrhage, Traumatic D020201 1 associated lipids
Migraine without Aura D020326 1 associated lipids
Mouth, Edentulous D009066 1 associated lipids
Anthrax D000881 1 associated lipids
Egg Hypersensitivity D021181 1 associated lipids
Leukostasis D018921 1 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Capillary Leak Syndrome D019559 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Hemorrhagic Fever, American D006478 2 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Ileitis D007079 2 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Jaundice, Obstructive D041781 2 associated lipids
Multiple Trauma D009104 2 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Eche N et al. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). 1986 Thromb. Res. pmid:3726808
Kakishita E et al. Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. 1990 Thromb. Res. pmid:2082481
Powling MJ and Hardisty RM Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. 1986 Thromb. Res. pmid:3787566
Chang GT et al. Purification and characterization of a new anticoagulant protein, PP27, from placenta. 2005 Thromb. Res. pmid:16122555
Siffert W et al. Inhibition of platelet aggregation by amiloride. 1986 Thromb. Res. pmid:3787567
Simon MF et al. Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. 1987 Thromb. Res. pmid:3576518
Alam I and Silver MJ Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. 1987 Thromb. Res. pmid:3576519
Liu X et al. Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. 2014 Thromb. Res. pmid:25223809
Hanss M and Dechavanne M 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. 1988 Thromb. Res. pmid:3126559
Okamoto M et al. Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. 1986 Thromb. Res. pmid:3754990
Bretschneider E et al. ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. 1994 Thromb. Res. pmid:7992234
Jones KP et al. Salivary PAF in acute myocardial infarction and angina: changes during hospital treatment and relationship to cardiac enzymes. 1994 Thromb. Res. pmid:7992251
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Juhan-Vague I et al. Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. 1985 Thromb. Res. pmid:3923649
Violi F et al. Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate. 1989 Thromb. Res. pmid:2506658
Kurose I et al. Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. 1991 Thromb. Res. pmid:1650966
Valone FH Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. 1987 Thromb. Res. pmid:3590086
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. 1987 Thromb. Res. pmid:3590110
Brown JE and Thuy LP The binding of bovine platelet aggregating factor to human platelets. 1981 Apr 1-15 Thromb. Res. pmid:7292446
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. 1987 Thromb. Res. pmid:3647677
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Catalán RE et al. Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. 1994 Thromb. Res. pmid:7974386
Valone FH Platelet-activating factor binding and metabolism during human platelet aggregation. 1988 Thromb. Res. pmid:3400077
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Lalau Keraly C et al. Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. 1984 Thromb. Res. pmid:6740569
Suttorp N et al. Stimulation of PAF-synthesis in pulmonary artery endothelial cells by Staphylococcus aureus alpha-toxin. 1992 Thromb. Res. pmid:1440526
Bernat A and Herbert JM Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. 1994 Thromb. Res. pmid:8073411
Pletscher A et al. LDL induced shape change reaction of platelets is not due to PAF. 1989 Thromb. Res. pmid:2609294
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Valone FH and Johnson B Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. 1985 Thromb. Res. pmid:4082115
Joseph R et al. Platelet-activating factor and red blood cells. 1989 Thromb. Res. pmid:2734734
Kohayakawa M and Inoue K Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1986 Thromb. Res. pmid:3083530
Ostermann G et al. The role of lipoproteins in the degradation of platelet-activating factor. 1986 Thromb. Res. pmid:3798402
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Battistini B et al. Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. 1990 Thromb. Res. pmid:2278035
Ostermann G et al. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids. 1991 Thromb. Res. pmid:2028445
Garcia JG et al. Effect of platelet activating factor on leukocyte-endothelial cell interactions. 1988 Thromb. Res. pmid:2842887
Suzuki K et al. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. 1980 Feb 1-15 Thromb. Res. pmid:6966083
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Ostermann G et al. The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. 1988 Thromb. Res. pmid:3232123
Avdonin PV et al. Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. 1988 Thromb. Res. pmid:3232128
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Avdonin PV et al. Evidence for the receptor-operated calcium channels in human platelet plasma membrane. 1987 Thromb. Res. pmid:2438805
Kinlough-Rathbone RL et al. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. 1999 Thromb. Res. pmid:10527409
Csáki C et al. Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. 1992 Thromb. Res. pmid:1412179
May JA et al. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. 1997 Thromb. Res. pmid:9361371
Patterson WR et al. Aggregation of killer whale platelets. 1993 Thromb. Res. pmid:8327987